Symptomatic bradycardia and heart block: workup and management
Bradycardia (HR <50) matters when it causes symptoms or instability, or reflects high-grade AV block. Treat instability with atropine, chronotropes or pacing, look for reversible causes (drugs, ischemia, hyperkalemia, hypothyroidism, Lyme), and decide on permanent pacing.
Working diagnosis
Adult · US guidelines
Draft · awaiting physician review
01Orient
What's new in the evidence
- 2025 AHA adult ALS guideline: atropine 1 mg IV every 3–5 min (max 3 mg); transcutaneous pacing or epinephrine/dopamine infusion if ineffective
- 2018 ACC/AHA/HRS bradycardia guideline remains current: treat reversible causes before permanent pacing
- If a needed beta-blocker or antiarrhythmic is causing bradycardia, proceeding to pacing without a washout is reasonable
Differential diagnoses
- Sinus node dysfunction (sick sinus, tachy-brady syndrome)
- Second-degree Mobitz II or third-degree AV block (can't miss)
- Drugs: beta-blockers, nondihydropyridine CCBs, digoxin, amiodarone, ivabradine, clonidine
- Hyperkalemia (can't miss)
- Inferior MI (can't miss)
- Hypothyroidism, hypothermia, raised ICP, Lyme carditis, infiltrative disease (sarcoid, amyloid)
02Assess
Risk scores and decision tools
- Instability: hypotension, altered mental status, ischemic chest pain, acute heart failure, shock
- Level of block: narrow QRS escape (nodal, atropine-responsive) vs wide QRS (infranodal, needs pacing)
- Lyme carditis risk (Suspicious Index in Lyme Carditis)
Key history questions
- Syncope, presyncope, fatigue, dyspnea, chest pain
- Medication list and recent changes, overdose
- Tick exposure, rash; recent travel
- Thyroid, kidney disease; sleep apnea
- Prior cardiac surgery or TAVR
Examination findings
- Hemodynamics, perfusion, mental status
- Cannon a waves, variable S1 (AV dissociation)
- Signs of heart failure
- Hypothermia, signs of hypothyroidism
03Investigate
Initial investigations
- 12-lead ECG and continuous telemetry
- BMP (potassium), magnesium, troponin, TSH
- Digoxin level if applicable; glucose
Advanced investigations
- Echocardiogram
- Lyme serology in endemic areas
- Ambulatory monitoring or EP study for intermittent symptoms
- Cardiac MRI or PET for suspected infiltrative disease in younger patients
04Treat
Immediate management
- Unstable: atropine 1 mg IV every 3–5 minutes (max 3 mg); less effective in infranodal block
- Transcutaneous pacing with analgesia/sedation if atropine fails
- Epinephrine 2–10 mcg/min or dopamine 5–20 mcg/kg/min infusion as a bridge
- Treat hyperkalemia urgently; antidotes for drug toxicity (glucagon for beta-blocker, calcium/high-dose insulin for CCB, digoxin immune Fab)
First-line treatment
- Stop or reduce culprit drugs
- Transvenous temporary pacing for persistent high-grade block
- Lyme carditis: IV ceftriaxone and temporary pacing; block usually resolves
Second-line treatment
- Permanent pacemaker for symptomatic sinus node dysfunction or Mobitz II/third-degree block without a reversible cause
- Isoproterenol infusion as a bridge when ischemia is unlikely
Specialist referrals
- Cardiology/electrophysiology for pacing
- ICU or CCU for unstable patients or temporary pacing
05Disposition
Admission criteria
- Mobitz II or third-degree block
- Syncope with bradycardia
- Hemodynamic compromise or need for chronotropes or pacing
Safe discharge criteria
- Asymptomatic sinus bradycardia or first-degree/Mobitz I block with reversible cause addressed
- Outpatient monitoring arranged
Follow-up timing
- Device clinic 1–2 weeks after pacemaker
- Cardiology within 2–4 weeks if monitored outpatient
Patient instructions
- Do not restart rate-slowing drugs without review
- Return for fainting or breathlessness
Monitoring
- Continuous telemetry
- Pacing threshold checks if temporary wire
Clinical pearls and pitfalls
- Asymptomatic sinus bradycardia during sleep or in athletes needs no treatment
- Inferior MI often causes transient nodal block; anterior MI with block suggests extensive infarction
- Bradycardia, renal failure, AV nodal blocker and hyperkalemia together (BRASH syndrome) need correction of all components
RefGuidelines and landmark evidence
For education only. Typical adult starting points; confirm doses against renal function, allergies, interactions and your institution's protocols. Not a substitute for clinical judgment or senior review.